4.7 Review

Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects

期刊

VACCINES
卷 10, 期 8, 页码 -

出版社

MDPI
DOI: 10.3390/vaccines10081272

关键词

head and neck squamous cell carcinoma; neoantigen; vaccine; adoptive cell therapy; immunotherapy

资金

  1. Science and Technology Research Project of Hubei Province [2021CFB210]

向作者/读者索取更多资源

Neoantigens, abnormal proteins produced by genetic mutations, have immunogenicity and represent specific targets for precision immunotherapy. Neoantigen vaccines and adoptive cell therapy targeting neoantigens have become research hotspots in the treatment of head and neck squamous cell carcinoma (HNSCC). This paper reviews recent trials related to neoantigen vaccine treatments for HNSCC, introduces adoptive cell therapy targeting neoantigens, and discusses the potential of neoantigens in HNSCC treatment.
Neoantigens are abnormal proteins produced by genetic mutations in somatic cells. Because tumour neoantigens are expressed only in tumour cells and have immunogenicity, they may represent specific targets for precision immunotherapy. With the reduction in sequencing cost, continuous advances in artificial intelligence technology and an increased understanding of tumour immunity, neoantigen vaccines and adoptive cell therapy (ACT) targeting neoantigens have become research hotspots. Approximately 900,000 patients worldwide are diagnosed with head and neck squamous cell carcinoma (HNSCC) each year. Due to its high mutagenicity and abundant lymphocyte infiltration, HNSCC naturally generates a variety of potential new antigen targets that may be used for HNSCC immunotherapies. Currently, the main immunotherapy for HNSCC is use of immune checkpoint inhibitors(ICIs). Neoantigen vaccines and adoptive cell therapy targeting neoantigens are extensions of immunotherapy for HNSCC, and a large number of early clinical trials are underway in combination with immune checkpoint inhibitors for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this paper, we review recent neoantigen vaccine trials related to the treatment of HNSCC, introduce adoptive cell therapy targeting neoantigens, and propose a potential treatment for HNSCC. The clinical application of immune checkpoint inhibitor therapy and its combination with neoantigen vaccines in the treatment of HNSCC are summarized, and the prospect of using neoantigen to treat HNSCC is discussed and proposed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据